Norden Gregory 4

What Happened
Gregory Norden, a director of Praxis Precision Medicines (PRAX), was awarded two equity grants on June 10, 2026: 1,371 restricted stock units (RSUs) and 648 derivative awards. Both grants were reported at $0.00 (i.e., no cash purchase). The RSUs convert into common shares and vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual meeting. The 648-share derivative award vests in 12 equal monthly installments beginning July 10, 2026 and finishing on the earlier of June 10, 2027 or the 2027 annual meeting.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
• Consideration: $0.00 per share (awards/grants, not purchases).
• Awards: 1,371 RSUs (settled only in shares) and 648 derivative shares (monthly vesting).
• Vesting: RSUs vest in one installment by June 10, 2027 (or at 2027 annual meeting); derivative vests monthly from July 10, 2026 through June 10, 2027 (or earlier at the 2027 annual meeting).
• Shares owned after transaction: not specified in the filing.
• Footnotes: RSUs are payable only in common stock and are reported in Table 1 per SEC guidance.

Context
These are grants/awards to a director (compensation/retention), not open‑market purchases or sales, so they do not by themselves signal buying or selling intent. RSUs and similar derivative awards are common for board compensation; they vest over time and will convert to actual shares only if vesting conditions are met.